首页 > 市场调查报告书 > 製药

以基因为基之药物开发

市场调查报告书

商品编码

1566127

药物基因体学市场规模、份额、成长分析，按产品/服务、按技术、按疾病领域、按应用、按地区 - 行业预测，2024-2031

Pharmacogenomics Market Size, Share, Growth Analysis, By Product & Service, By Technology, By Disease Area, By Application, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年药物基因体学市场规模为61.5亿美元，从2023年的66.7亿美元成长到2031年的127.8亿美元，复合年增长率预计为8.47%。

受基因组研究进步、个人化医疗兴起以及精准医疗进步的影响，全球市场情势正在经历强劲成长和转型。人们对个人化治疗选择的认识不断提高，加上基因组测试越来越多地融入临床通讯协定，正在推动市场扩张，尤其是在慢性病变得更加普遍的情况下。此外，基因组资料和电子健康记录的融合，以及标靶治疗的出现，正在显着增加市场活力。製药公司、研究机构和监管机构之间的合作也大大推进了药物基因组学研究。然而，市场面临挑战，包括基因检测的高成本、限制性的报销政策以及迫切需要广泛的研发工作。解决这些障碍并最大限度地在临床实践中使用药物基因体学对于市场的持续成功至关重要。值得注意的是，美国药物基因体学领域预计在未来几年将保持持续的复合年增长率，显示该创新领域未来发展的巨大潜力和投资机会。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN
Danaher Corporation
Laboratory Corporation of America Holdings
Eurofins Scientific
Charles River Laboratories
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Becton, Dickinson and Company
Revvity
IQVIA, Inc.
Mesa Labs, Inc.
Medpace, Inc.
MGI Tech Co., Ltd.
PacBio
Takara Bio Inc.
New England Biolabs
BGI
Novogene Co., Ltd.
Sophia Genetics
Fios Genomics
Personalis, Inc.
NeoGenomics Laboratories
BioAI Health Inc.
Macrogen, Inc.

简介目录

Product Code: SQMIG35G2248

Pharmacogenomics Market size was valued at USD 6.15 billion in 2022 and is poised to grow from USD 6.67 billion in 2023 to USD 12.78 billion by 2031, growing at a CAGR of 8.47% in the forecast period (2024-2031).

The global pharmacogenomics market is witnessing robust growth and a transformative landscape, largely influenced by breakthroughs in genomic research, the rise of personalized medicine, and the advancement of precision healthcare. A surge in awareness regarding personalized treatment options, coupled with an increasing integration of genomic testing into clinical protocols, is propelling market expansion, especially as chronic diseases become more prevalent. Furthermore, the amalgamation of genomic data with electronic health records, alongside the emergence of targeted therapies, is significantly enhancing market dynamics. Collaborative efforts among pharmaceutical firms, research institutions, and regulatory agencies are also driving considerable progress in pharmacogenomic research. Nonetheless, the market faces challenges, including the high costs associated with genetic testing, restrictive reimbursement policies, and a pressing necessity for extensive R&D efforts. Addressing these barriers and maximally utilizing pharmacogenomics in clinical settings will be crucial for the ongoing success of the market. In particular, the U.S. pharmacogenomics sector is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast year, indicating strong potential for future development and investment opportunities within this innovative field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacogenomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacogenomics Market Segmental Analysis

Global Pharmacogenomics Market is segmented by Product & Service, Technology, Disease Area, Application, End User and region. Based on Product & service, the market is segmented into Kits & Reagents (Sequencing Kits and Reagents, PCR Kits and Reagents, Microarray Kits and Reagents, Other Kits and Reagents), Service. Based on Technology, the market is segmented into Sequencing, PCR, Microarray, and Other Technologies. Based on Disease Area, the market is segmented into Cancer, Cardiovascular, Neurological Diseases, Other Disease Areas. Based on Application, the market is segmented into Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development. Based on End User, the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Pharmacogenomics Market

The rising demand for personalized medicine significantly propels the global pharmacogenomics market, as healthcare stakeholders increasingly recognize the importance of tailoring drug therapies to individual genetic profiles. By leveraging pharmacogenomic insights, clinicians can optimize medication selection and dosages, enhancing efficacy and minimizing adverse effects, thereby leading to safer treatment regimens. This shift towards precision medicine not only improves patient health outcomes but also fosters healthcare efficiency and cost-effectiveness. As more healthcare systems integrate pharmacogenomic testing into routine practices, the market is poised for substantial growth, reflecting a broader trend towards individualized healthcare solutions that cater to each patient's unique genetic makeup.

Restraints in the Pharmacogenomics Market

The global pharmacogenomics market faces significant restraint due to the high costs associated with genetic testing and genomic analysis. These advanced tests necessitate sophisticated laboratory infrastructure and specialized expertise, resulting in expensive procedures that can limit accessibility for patients, particularly in developing regions where healthcare resources are constrained. Moreover, the complex nature of interpreting and integrating genetic data into clinical workflows demands additional specialized training and resources. These financial and technical challenges create substantial barriers to the widespread adoption of pharmacogenomic services, ultimately affecting the market's growth potential and the realization of personalized medicine benefits across diverse populations.

Market Trends of the Pharmacogenomics Market

A prominent trend in the global pharmacogenomics market is the widespread integration of personalized medicine, which tailors drug therapies to align with an individual's unique genetic profile. This paradigm shift, fueled by advancements in genomic research and increased accessibility to genetic testing technologies, empowers healthcare providers to optimize treatment efficacy and mitigate adverse drug reactions. As the healthcare industry increasingly recognizes the importance of genetic insights in medication management, the implementation of pharmacogenomics in clinical settings is anticipated to accelerate, heralding a new era of targeted therapies. This evolution not only enhances patient outcomes but also signifies robust growth potential for the pharmacogenomics market in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Value Chain Analysis
Supply Chain Analysis
Regulatory Landscape
Pricing Analysis
Patent Analysis
Customer & Buying Criteria Analysis

Pharmacogenomics Market, By Product & Service

Market Overview
Kits & Reagents
- Sequencing Kits & Reagents
- PCR Kits & Reagents
- Microarray Kits & Reagents
- Other Kits & Reagents
Services

Pharmacogenomics Market, By Technology

Market Overview
Sequencing
PCR
Microarray
Other Technologies

Pharmacogenomics Market, By Application

Market Overview
Personalized Medicine
Clinical Research
Drug Discovery & Preclinical Development

Pharmacogenomics Market, By Disease Area

Market Overview
Cancer
Cardiovascular Disease
Neurological Disorders
Other Disease Areas

Pharmacogenomics Market, By End User

Market Overview
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations

Pharmacogenomics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revvity
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesa Labs, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MGI Tech Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PacBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novogene Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sophia Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fios Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAI Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrogen, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments